Oncology

Your Article Summary

See Latest Articles

Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial
The American Journal of Surgery, 06/29/09

Nelson JC et al. – Study reports that the locoregional control, complications, and cosmetic outcomes from MammoSite partial breast irradiation (APBI) at the 4-year update are acceptable and similar to results seen with other forms of APBI.

• A 4-year update on the efficacy, cosmetic results, and complications of MammoSite breast brachytherapy in pts enrolled in the American Society of Breast Surgeons registry trial is presented
• 1,449 breasts in 1,440 pts with early stage BCa undergoing breast-conserving therapy
• Pts were treated with adjuvant APBI (34 Gy in 3.4-Gy fractions) delivered with the MammoSite device
• Median follow-up period for the entire group was 36.1 months

• 3-yr actuarial rate of ipsilateral breast tumor recurrence was 2.15%
• 3-yr actuarial rate of axillary recurrence was 0.36%
• Complication rates were: infection, 9.5%; seroma, 26.8%, symptomatic seroma, 12.7%; and fat necrosis, 2.0%
• Percentages of breasts with good or excellent cosmetic results were: 12 mo, 95%; 24 mo, 94%; 36 mo, 94%; and 48 mo, 91%

Today in Breast...keeping you current

Receive free subspecialty "5-minute updates" via email

Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group
Journal of Clinical Oncology, 10/19/09

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09

Pomegranate fruit extract impairs invasion and motility in human breast cancer
Integrative Cancer Therapies , 10/12/09

See All of Breast